Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 342 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Impairments Clear all
Completed Phase 1 Interventional Results available

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

NCT03814005
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions
Azacitidine, Pevonedistat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

NCT02648347
View directory record Official record
Conditions
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
208
States / cities
Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

NCT02571036
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
Interventions
DCC-2618
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 5, 2026, 2:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cognitive Impairment in Kidney Disease

NCT00905619
View directory record Official record
Conditions
Kidney Insufficiency, Chronic
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

NCT02578082
View directory record Official record
Conditions
Renal Impairment
Interventions
TD-4208
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glasdegib Renal Impairment Study

NCT03596567
View directory record Official record
Conditions
Renal Impairment
Interventions
Glasdegib single 100 mg dose in normal healthy subjects, Glasdegib single 100 mg dose in moderate renal impairment subjects, Glasdegib single 100 mg dose in severe renal impairment subjects
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

NCT06402721
View directory record Official record
Conditions
Chronic Kidney Disease, Hepatic Impairment
Interventions
BAY3283142
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Renal Impairment Study of PF-06700841

NCT04260464
View directory record Official record
Conditions
Healthy Volunteer, Renal Impairment
Interventions
PF-06700841
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)

NCT06814119
View directory record Official record
Conditions
Healthy, Renal Impairment
Interventions
Calderasib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Orlando, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

NCT03242252
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

NCT01069926
View directory record Official record
Conditions
Glucose Lowering
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Orlando, Florida • Overland Park, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2010 · Synced Oct 5, 2026, 2:45 PM EDT
Completed No phase listed Observational

Fanconi Syndrome Due to ARVs in HIV-Infected Persons

NCT00499187
View directory record Official record
Conditions
HIV Infections, Fanconi Syndrome, Kidney Disease, Renal Impairment
Interventions
Blood Draws
Procedure
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

NCT01555008
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Renal Impairment
Interventions
LX4211, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
6
States / cities
Anniston, Alabama • Chula Vista, California • Edgewater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

NCT06318676
View directory record Official record
Conditions
Renal Impairment
Interventions
Mezigdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 82 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in People With Renal Impairment

NCT07034768
View directory record Official record
Conditions
Renal Impairments
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

NCT02354937
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 30 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

NCT02327546
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AKB-6548, Ferrous Sulfate
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

NCT02441829
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Eleclazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
DeLand, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

NCT02062203
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Placebo, Moxifloxacin
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

NCT06157242
View directory record Official record
Conditions
Bacterial Infections
Interventions
Xeruborbactam Oral Prodrug, Ceftibuten
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 5, 2026, 2:45 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

NCT04020055
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat HCl 150 mg
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Cleveland, Ohio • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 5, 2026, 2:45 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions

NCT07741604
View directory record Official record
Conditions
Renal Impairment
Interventions
RO7795081
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Miami Lakes, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 5, 2026, 2:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320
View directory record Official record
Conditions
Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions
Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 5, 2026, 2:45 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

NCT01359579
View directory record Official record
Conditions
Renal Impairment
Interventions
varespladib methyl
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 5, 2026, 2:45 PM EDT